HSBC Holdings
KROS icon

HSBC Holdings’s Keros Therapeutics KROS Stock Holding History

HSBC Holdings’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$761K Buy
69,926
+15,940
+30% +$178K ﹤0.01% 2080
2026
Q1 		$599K Buy
+53,986
New +$834K ﹤0.01% 2140
2024
Q2 		– Sell
-46,419
Closed -$3.07M – 3075
2024
Q1 		$3.07M Buy
+46,419
New +$2.75M ﹤0.01% 1292

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

HSBC Holdings's KROS Position: Q2 2026 in Review

HSBC Holdings increased its Keros Therapeutics (KROS) stake by 30% in Q2 2026, buying an estimated $178K and bringing the position to 69,926 shares worth $761K. The position accounts for ﹤0.01% of the portfolio, ranked #2080.

HSBC Holdings first reported a position in KROS in Q1 2024 and has held it in 3 quarters since. The position peaked at $3.07M in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • HSBC Holdings held 69,926 shares of Keros Therapeutics worth $761K as of Q2 2026.
  • HSBC Holdings bought 15,940 Keros Therapeutics shares in Q2 2026, an estimated $178K.
  • Keros Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2080 holding.
  • HSBC Holdings first reported a position in Keros Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • HSBC Holdings's Keros Therapeutics position peaked at $3.07M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.